139 related articles for article (PubMed ID: 36180906)
1. A genetic map of the chromatin regulators to drug response in cancer cells.
Chen B; Li P; Liu M; Liu K; Zou M; Geng Y; Zhuang S; Xu H; Wang L; Chen T; Li Y; Zhao Z; Qi L; Gu Y
J Transl Med; 2022 Sep; 20(1):438. PubMed ID: 36180906
[TBL] [Abstract][Full Text] [Related]
2. FACER: comprehensive molecular and functional characterization of epigenetic chromatin regulators.
Lu J; Xu J; Li J; Pan T; Bai J; Wang L; Jin X; Lin X; Zhang Y; Li Y; Sahni N; Li X
Nucleic Acids Res; 2018 Nov; 46(19):10019-10033. PubMed ID: 30102398
[TBL] [Abstract][Full Text] [Related]
3. The synergistic interaction landscape of chromatin regulators reveals their epigenetic regulation mechanisms across five cancer cell lines.
Cao M; Wang L; Xu D; Bi X; Guo S; Xu Z; Chen L; Zheng D; Li P; Xu J; Zheng S; Wang H; Wang B; Lu J; Li K
Comput Struct Biotechnol J; 2022; 20():5028-5039. PubMed ID: 36187922
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
5. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
6. Circadian Clock Genes Are Correlated with Prognosis and Immune Cell Infiltration in Colon Adenocarcinoma.
He A; Huang Z; Zhang R; Lu H; Wang J; Cao J; Feng Q
Comput Math Methods Med; 2022; 2022():1709918. PubMed ID: 35116071
[TBL] [Abstract][Full Text] [Related]
7. Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells.
Han Y; Wang C; Dong Q; Chen T; Yang F; Liu Y; Chen B; Zhao Z; Qi L; Zhao W; Liang H; Guo Z; Gu Y
Mol Ther Nucleic Acids; 2019 Sep; 17():688-700. PubMed ID: 31400611
[TBL] [Abstract][Full Text] [Related]
8. Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer.
Zhu K; Liu X; Deng W; Wang G; Fu B
Hereditas; 2022 Feb; 159(1):13. PubMed ID: 35125116
[TBL] [Abstract][Full Text] [Related]
9. Gene expression and methylation profiles identified CXCL3 and CXCL8 as key genes for diagnosis and prognosis of colon adenocarcinoma.
Zhao QQ; Jiang C; Gao Q; Zhang YY; Wang G; Chen XP; Wu SB; Tang J
J Cell Physiol; 2020 May; 235(5):4902-4912. PubMed ID: 31709538
[TBL] [Abstract][Full Text] [Related]
10. Identification of long noncoding RNAs biomarkers for diagnosis and prognosis in patients with colon adenocarcinoma.
Huang W; Liu Z; Li Y; Liu L; Mai G
J Cell Biochem; 2019 Mar; 120(3):4121-4131. PubMed ID: 30269368
[TBL] [Abstract][Full Text] [Related]
11. A framework for identifying dysregulated chromatin regulators as master regulators in human cancer.
Ru B; Sun J; Kang Q; Tong Y; Zhang J
Bioinformatics; 2019 Jun; 35(11):1805-1812. PubMed ID: 30358822
[TBL] [Abstract][Full Text] [Related]
12. CRdb: a comprehensive resource for deciphering chromatin regulators in human.
Zhang Y; Zhang Y; Song C; Zhao X; Ai B; Wang Y; Zhou L; Zhu J; Feng C; Xu L; Wang Q; Sun H; Fang Q; Xu X; Li E; Li C
Nucleic Acids Res; 2023 Jan; 51(D1):D88-D100. PubMed ID: 36318256
[TBL] [Abstract][Full Text] [Related]
13. Identification of hub genes and construction of transcriptional regulatory network for the progression of colon adenocarcinoma hub genes and TF regulatory network of colon adenocarcinoma.
Wei S; Chen J; Huang Y; Sun Q; Wang H; Liang X; Hu Z; Li X
J Cell Physiol; 2020 Mar; 235(3):2037-2048. PubMed ID: 31612481
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
15. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
16. The prognostic effect of PNN in digestive tract cancers and its correlation with the tumor immune landscape in colon adenocarcinoma.
Zhang H; Jin M; Ye M; Bei Y; Yang S; Liu K
J Clin Lab Anal; 2022 Apr; 36(4):e24327. PubMed ID: 35257416
[TBL] [Abstract][Full Text] [Related]
17. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
Gao H; Xing F
BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
[TBL] [Abstract][Full Text] [Related]
18. Identification prognosis-associated immune genes in colon adenocarcinoma.
Miao Y; Wang J; Ma X; Yang Y; Mi D
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33140821
[TBL] [Abstract][Full Text] [Related]
19. Identification of gene modules and hub genes in colon adenocarcinoma associated with pathological stage based on WGCNA analysis.
Wang H; Liu J; Li J; Zang D; Wang X; Chen Y; Gu T; Su W; Song N
Cancer Genet; 2020 Apr; 242():1-7. PubMed ID: 32036224
[TBL] [Abstract][Full Text] [Related]
20. A potential prognostic prediction model of colon adenocarcinoma with recurrence based on prognostic lncRNA signatures.
Jin L; Li C; Liu T; Wang L
Hum Genomics; 2020 Jun; 14(1):24. PubMed ID: 32522293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
